Gambogic acid enhances proteasome inhibitor-induced anticancer activity
- 28 February 2011
- journal article
- Published by Elsevier BV in Cancer Letters
- Vol. 301 (2), 221-228
- https://doi.org/10.1016/j.canlet.2010.12.015
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Physiological levels of ATP negatively regulate proteasome functionCell Research, 2010
- Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivoInternational Journal of Cancer, 2009
- Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteinsMolecular Cancer Therapeutics, 2008
- Molecular Evidence for Increased Antitumor Activity of Gemcitabine by Genistein In vitro and In vivo Using an Orthotopic Model of Pancreatic CancerCancer Research, 2005
- Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cellsBiochemical Pharmacology, 2005
- Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823World Journal of Gastroenterology, 2005
- Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis.2004
- Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assayBioorganic & Medicinal Chemistry, 2003
- Protein degradation and protection against misfolded or damaged proteinsNature, 2003
- Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.Journal of Clinical Oncology, 1995